Biodexa Pharmaceuticals (BDRX) Income from Non-Controlling Interests (2014 - 2020)

Biodexa Pharmaceuticals (BDRX) has 6 years of Income from Non-Controlling Interests data on file, last reported at $670789.1 in Q4 2020.

• For the quarter ending Q4 2020, Income from Non-Controlling Interests rose 352.04% year-over-year to $670789.1; the trailing twelve-month figure through Dec 2016 stood at $4.0 million (up 562.8% YoY), and the FY2020 full-year result was $652346.3, up 346.82% from the prior year.
• Income from Non-Controlling Interests grew to $670789.1 in Q4 2020, from -$266145.1 in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $4.0 million in Q4 2016 to a low of -$3.5 million in Q4 2018.
• A 4-year average of $240377.2 and a median of $202322.0 in 2019 frame the typical range for Income from Non-Controlling Interests.
• Across the five-year window, Income from Non-Controlling Interests surged 562.8% in 2016 and jumped 92.3% in 2019, its largest moves.
• Tracing BDRX's Income from Non-Controlling Interests over 4 years: stood at $4.0 million in 2016, then slumped by 186.12% to -$3.5 million in 2018, then jumped by 92.3% to -$266145.1 in 2019, then jumped by 352.04% to $670789.1 in 2020.
• Business Quant data shows BDRX's Income from Non-Controlling Interests at $670789.1 in Q4 2020, -$266145.1 in Q4 2019, and -$3.5 million in Q4 2018.